Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making

JCO Precision Oncology

Volumn 2017, Issue 1, 2017, Pages 1-26

  Abida, Wassim ^a   Armenia, Joshua ^a   Gopalan, Anuradha ^a   Brennan, Ryan ^a   Walsh, Michael ^a   Barron, David ^a   Danila, Daniel ^a   Rathkopf, Dana ^a   Morris, Michael ^a   Slovin, Susan ^a   McLaughlin, Brigit ^a   Curtis, Kristen ^a   Hyman, David M ^a   Durack, Jeremy C ^a   Solomon, Stephen B ^a   Arcila, Maria E ^a   Zehir, Ahmet ^a   Syed, Aijazuddin ^a   Gao, Jianjiong ^a   Chakravarty, Debyani ^a   Vargas, Hebert Alberto ^a   Robson, Mark E ^a   Vijai, Joseph ^a   Offit, Kenneth ^a   Donoghue, Mark T A ^a   Abeshouse, Adam A ^a   Kundra, Ritika ^a   Heins, Zachary J ^a   Penson, Alexander V ^a   Harris, Christopher ^a   Taylor, Barry S ^a   Ladanyi, Marc ^a   Mandelker, Diana ^a   Zhang, Liying ^a   Reuter, Victor E ^a   Kantoff, Philip W ^a   Solit, David B ^a   Berger, Michael F ^a   Sawyers, Charles L ^a   Schultz, Nikolaus ^a   Scher, Howard I ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ADULT; AGED; APC GENE; AR GENE; ARTICLE; ATM GENE; CANCER GENETICS; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DNA DAMAGE REPAIR GENE; DNA REPAIR; DNA SEQUENCE; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INSERTION; GENE REARRANGEMENT; GENETIC ANALYSIS; GERMLINE MUTATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; PIK3CA GENE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 85028926936     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.17.00029     Document Type: Article

References (43)

1. Scher HI, Heller G: Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 55: 323-327, 2000
2. National Comprehensive Cancer Network: Prostate cancer (version 1.2015). https://www.nccn.org/patients/ guidelines/prostate/files/assets/common/downloads/files/prostate.pdf
3. Cancer Genome Atlas Research Network: The molecular taxonomy of primary prostate cancer. Cell 163:1011-1025, 2015
4. Robinson D, Van Allen EM, Wu YM, et al: Integrative clinical genomics of advanced prostate cancer. Cell 161: 1215-1228, 2015 [Erratum: Cell 162:454, 2015]
5. Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22, 2010
6. Grasso CS, Wu YM, Robinson DR, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243, 2012
7. Barbieri CE, Baca SC, Lawrence MS, et al: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685-689, 2012
8. Cheng HH, Pritchard CC, Boyd T, et al: Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castrationresistant prostate cancer. Eur Urol 69:992-995, 2016
9. Mateo J, Carreira S, Sandhu S, et al: DNA-repair defects and olaparib in metastatic prostate cancer.NEngl JMed 373: 1697-1708, 2015
10. Hyman DM, Solit DB, Arcila ME, et al: Precision medicine at Memorial Sloan Kettering Cancer Center: Clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today 20:1422-8, 2015
11. Cheng DT, Mitchell T, Zehir A, et al: MSK-IMPACT: A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251-264, 2015
12. cBioportal: cBio cancer genomics portal. http://www.cbioportal.org/study?id=prad_mskcc_2017
13. Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012
14. Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1, 2013
15. McGranahan N, Favero F, de Bruin EC, et al: Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 7:283ra54, 2015
16. Shen R, Seshan VE: FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for highthroughput DNA sequencing. Nucleic Acids Res 44:e131, 2016
17. Schrader KA, Cheng DT, Joseph V, et al: Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2:104-11, 2016
18. Joshi PM, Sutor SL, Huntoon CJ, et al: Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 289:9247-9253, 2014
19. Chang MT, Asthana S, Gao SP, et al: Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-163, 2016
20. Bajrami I, Frankum JR, Konde A, et al: Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 74:287-297, 2014
21. Buisson R, Dion-Côté AM, Coulombe Y, et al: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17:1247-1254, 2010
22. McCabe N, Turner NC, Lord CJ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115, 2006
23. Cremona CA, Behrens A: ATM signalling and cancer. Oncogene 33:3351-3360, 2014
24. Pritchard CC, Mateo J, Walsh MF, et al: Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443-453, 2016
25. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. Nature 500: 415-421, 2013 [Erratum: Nature 502:258, 2013]
26. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Deciphering signatures of mutational processes operative in human cancer. Cell Reports 3:246-259, 2013
27. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015
28. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014
29. Van Allen EM, Miao D, Schilling B, et al: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207-211, 2015
30. Chakravarty D, Gao J, Phillips SM, et al: OnkoKB: A precision oncology knowledge base. JCO Precis Oncol doi: 10.1200/PO.17.00011
31. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004
32. Taplin ME, Bubley GJ, Shuster TD, et al: Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 332:1393-1398, 1995
33. Visakorpi T, Hyytinen E, Koivisto P, et al: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406, 1995
34. Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261, 2005
35. Balbas MD, Evans MJ, Hosfield DJ, et al: Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499, 2013
36. Joseph JD, Lu N, Qian J, et al: A clinically relevant androgen receptor mutation confers resistance to secondgeneration antiandrogens enzalutamide and ARN-509. Cancer Discov 3:1020-1029, 2013
37. Duff J, McEwan IJ: Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol 19:2943-2954, 2005
38. Boysen G, Barbieri CE, Prandi D, et al: SPOP mutation leads to genomic instability in prostate cancer. eLife 4:e09207, 2015
39. Aparicio AM, Shen L, Tapia EL, et al: Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res 22:1520-1530, 2016
40. Zhou Z, Flesken-Nikitin A, Corney DC, et al: Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898, 2006
41. Mu P, Zhang Z, Benelli M, et al: SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer. Science 355:84-88, 2017
42. Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature 436:725-730, 2005
43. Hong MK, Macintyre G, Wedge DC, et al: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605, 2015